Cyclophosphamide News and Research

RSS
Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.
Triptolide-based treatment prolongs symptom-free survival in preclinical medulloblastoma models

Triptolide-based treatment prolongs symptom-free survival in preclinical medulloblastoma models

New curative treatment for sickle cell disease shows promising results in international trial

New curative treatment for sickle cell disease shows promising results in international trial

New stem cell transplant approach may expand donor pool for high-risk blood cancer patients

New stem cell transplant approach may expand donor pool for high-risk blood cancer patients

Pigeon virus causes fatal neurological disease in young leukemia patient

Pigeon virus causes fatal neurological disease in young leukemia patient

Autologous stem cell transplant shows promise for young patients with severe juvenile systemic sclerosis

Autologous stem cell transplant shows promise for young patients with severe juvenile systemic sclerosis

Exploring the link between drugs and microbiota: a growing imperative in precision medicine

Exploring the link between drugs and microbiota: a growing imperative in precision medicine

ACT and personalized cancer vaccine combo shows efficacy in ovarian cancer patients

ACT and personalized cancer vaccine combo shows efficacy in ovarian cancer patients

Subclonal neoantigens present a key roadblock in MMRd tumor immunotherapy success

Subclonal neoantigens present a key roadblock in MMRd tumor immunotherapy success

New way to administer CAR-T-cell therapy could lead to fewer side effects

New way to administer CAR-T-cell therapy could lead to fewer side effects

New standard more effective at preventing graft-versus-host disease

New standard more effective at preventing graft-versus-host disease

Phase I clinical study of TCR NK cell therapy for sarcoma expected to commence later this year

Phase I clinical study of TCR NK cell therapy for sarcoma expected to commence later this year

First-in-human clinical study begins investigating the duoCAR T-cell therapy for treatment of HIV

First-in-human clinical study begins investigating the duoCAR T-cell therapy for treatment of HIV

Novel T cell receptor therapy shows early promise for treating solid tumors

Novel T cell receptor therapy shows early promise for treating solid tumors

Exploring remdesivir resistance in COVID-19-infected transplant recipients

Exploring remdesivir resistance in COVID-19-infected transplant recipients

Tumor-infiltrating lymphocytes therapy treats cancers at a large scale

Tumor-infiltrating lymphocytes therapy treats cancers at a large scale

Doggybone DNA COVID-19 vaccine can effectively neutralize SARS-CoV-2 variants

Doggybone DNA COVID-19 vaccine can effectively neutralize SARS-CoV-2 variants

Combination therapy shows promise for treating triple-negative breast cancer

Combination therapy shows promise for treating triple-negative breast cancer

NK cells complexed with bispecific antibody elicit high response rate in patients with resistant lymphomas

NK cells complexed with bispecific antibody elicit high response rate in patients with resistant lymphomas

Neutrophils found to initiate COVID-19-associated olfactory epithelial damage in hamsters

Neutrophils found to initiate COVID-19-associated olfactory epithelial damage in hamsters

COVID-19 symptoms found to vary in different immune contexts

COVID-19 symptoms found to vary in different immune contexts

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.